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VACCINATION AGAINST BABESIA
Implications for malaria ?
BLOCKED CAPILLARIES-BABESIA
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In clinical babesiosis capillaries become blocked
Brain section of B. canis infected dog Gut section of B. canis infected dog
BLOCKED CAPILLARIES-BABESIA
3
B. bovis infected red blood cell B. canis infected red blood cell
Infected red blood cells adhere to the lining of blood vessels 
(margination), but ridges are not absolutely required
Courtesy of Brian Cooke
CIRCULATORY DISTURBANCES-BABESIA
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B. canis infected dogNot-infected control dog
•Anaemia
•Prolonged capillary refill time
•Poor tissue perfusion
•Sharp pulse (decreased 
capillary resistance)
CIRCULATORY DISTURBANCES-BABESIA
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Collapsed arterioles in the mucosae of a B. canis-infected dog (left). Control on 
the right. Note absence of filled arterioles in infected dog
COMPENSATED HYPOTENSION-BABESIA
MEAN ARTERIAL PRESSURE
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B. canis infected dogs (n=3). Arrow indicates day of cure of 10^6 group
Dogs develop hypotension upon B. canis infection. Non-cured dogs 
restored blood pressure in two days (blue bar)
Schetters et al. 2009 Vet Parasitol. 162, 7-15
COMPENSATED HYPOTENSION-BABESIA
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During the phase of hypotension water is retained, reflected in increased body weight
-dogs were kept in metabolic cages after B. canis infection-
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Water balance in B. canis infected dogs (n=2) Body weight increase in B. canis infected dogs (n=2)
Schetters et al. 1998 Ann. Trop. Med. & Parasitol. 513-519
COMPENSATED HYPOTENSION-BABESIA
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creatinin PCV
During hypotension water is retained, reflected in dilution of blood components
-dilution of creatinin is similar to that of the red blood cells-
40
40 60 80 100 120
 Rel creatinin (%)
Dynamics of creatinin and red blood cell 
concentrations in B. canis infected dogs (n=5)
Correlation between concentrations of creatinin and 
red blood cells in B. canis infected dogs (n=5)
Schetters et al. 1997 Vet. Parasitol. 73, 35-41
COMPENSATED HYPOTENSION-MALARIA
Orthostatic hypotension
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9Brooks et al. 1967 Am. J. Med. 43, 735-744
0
20
Diastolic Systolic
Blood pressure Pulse 
pressure
Arterial 
pressure
Standing
Due to decreased capillary resistance 
orthostatic hypotension leads to dizziness 
and syncope (fainting)
COMPENSATED HYPOTENSION-MALARIA
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Feldman and Murphy 1945 J. Clin. Invest. 24, 780-792
During hypotension water is retained, reflected in dilution of blood components
Dynamics of red blood cell concentrations in patients 
receiving therapeutic P. falciparum infection 
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acute illness convalescence
Malloy et al. 1967 Am. J. Med. 43, 745-750
Plasma volume changes in P. falciparum patients 
receiving therapeutic treatment (n=23). Average change 
is 485 ml, 12.5% (p<0.001)
CONCLUSIONS
• Early in Babesia infection dogs develop hypotension
• Hypotension is compensated by increase of blood volume in 2-3 
days
• Haematocrit decreases are largely the result of haemodilution
• Capillary resistance remains low which reduces blood flow through 
BLOCKED CAPILLARIES-BABESIA
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capillaries
• Reduced blood flow facilitates adherence of infected red blood cells
• Similar processes occur in malaria
• These aspects are largely neglected
VACCINATION-BABESIA
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Supernatants of in vitro cultures of the parasite can be used as vaccines
VACCINATION-BABESIA
Antigen production (SPA) Adjuvant production (saponin)
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A single dose is supernatant antigen (SPA) produced by  1 x 10e8 infected 
erythrocytes. Quil A (250 ug/ml) is used as adjuvant. A single dose volume is 1ml.
Two subcutaneous injections with 3-week interval
VACCINATION-BABESIA
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Time after infection (days)
Vaccinated Control
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Control Vaccinated
Vaccination with SPA controls excessive PCV and creatinin decreases
Schetters et al. 1997 Vet. Parasitol. 73, 35-41
Effect of vaccination of dogs with SPA on the red blood 
cell concentration (PCV) in blood. Data represent the 
average values from vaccinated and controls dogs (n=5)
Effect of vaccination of dogs with SPA on the creatinin 
concentration in blood. Data represent the average 
values from vaccinated and controls dogs (n=5)
VACCINATION-BABESIA
R2 = 0.9049
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Because both parameters are affected to the same extent it is concluded 
that vaccination with SPA limits haemodilution 
Schetters et al. 1997 Vet. Parasitol. 73, 35-41
Effect of vaccination of dogs with SPA on the red blood cell concentration 
(PCV) and creatinin concentration in blood. Data represent the difference 
between values from vaccinated dogs and controls dogs (n=5)
Protected dog
VACCINATION-BABESIA
Vaccinated Control
16Schetters et al. 1996 Parasite Immunol. 18, 1-6
Not peripheral parasitaemia but the level of SPA in plasma correlates with protection
Dynamics of parasitaemia (squares) and SPA 
concentrations (crosses) in vaccinated dogs 
(n=5)
Dynamics of parasitaemia (squares) and SPA 
concentrations (crosses) in control dogs (n=5)
Antibodies against SPA
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Schetters et al. 1996 Parasite Immunol. 18, 1-6
The antibody response against SPA correlates with protection
CONCLUSIONS
• SPA of Babesia canis parasites cause disease
• Vaccination with SPA induces protection
• Protection is reflected in decreased SPA in plasma
• Protection is associated with an antibody response against SPA
• In experimental infections anti-SPA response is absent
VACCINATION-BABESIA
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• Vaccine-induced protection is essentially different from infection-induced 
protection
ANALYSIS SUPERNATANT ANTIGENS
SPA1a
SPA1b
0        15        30      60     120    240 minutes
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A doublet at Mr 38-40kDa is produced by B. canis after 15 
minutes pulse and chased at different time points
ANALYSIS SUPERNATANT ANTIGENS
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Vaccination-challenge serum Normal dog serum
SPA Mr 38-40kDa
Vaccination-challenge serum recognizes SPA (mainly Mr 38kDa molecule)
-western blot analysis-
DISCOVERY OF THE SPA1 GENE OF BABESIA CANIS
• The major antigens from SPA of B. canis were purified
• Partial amino acid sequences were revealed
• The genome of B. canis was sequenced
VACCINATION REC. SPA 1 ANTIGEN
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• The gene encoding for SPA1 was identified
RECOMBINANT SPA 1 ANTIGEN
SPA1 GENE OF BABESIA CANIS 
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Signal sequences are boxed (GPI-anchored!)
In blue, peptides from purified SPA1b Mr40kDa (technique 1)
In blue/italics, peptide from purified SPA1a Mr 38kDa (technique 1)
In red, peptides from SPA1b (technique 2)
In yellow circles, cysteines that can lead to intramolecular di-sulphide 
bond
The SPA doublet is encoded by a single gene
40 kDa
RECOMBINANT SPA 1 ANTIGEN
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Production of recombinant SPA1 antigen in E. coli
25 kDa
30 kDa
Soluble fraction Purified BcSPA1 Refolded BcSPA1
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rSPA1 antibody titers in dogs
SEROCONVERSION RECOMBINANT SPA 1 
ANTIGEN
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Vaccination (day 0, 21 and 42) with Quil A adjuvant. Challenge day 56.
CLINICAL SIGNS
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Vaccinated dogs are protected from clinical disease
-circulatory problems in control dogs from day 11 onwards-
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Packed cell volume in dogs after challenge infection with BcA
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Vaccinated dogs showed limited decreases in packed cell volume
PARASITAEMIA
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Development of parasitaemia is limited in vaccinated dogs
VACCINATION REC. SPA 1 ANTIGEN
CONCLUSIONS -Babesia
• Vaccination of dogs with recombinant SPA1 protects against virulent 
challenge infection
• Protection is reflected in:
• Limited decrease in packed cell volume
• Restricted development of parasitaemia
• Reduction in clinical signs (circulatory stress)
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• It is hypothesized that vaccination interferes with pathological processes 
that lead to parasite localization which favours parasite proliferation 
(chronic infection)
• Similar pathological processes have been described in malaria and other 
systemic diseases
VACCINATION-MALARIA
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The vaccine principle was claimed 
to work in the P. falciparum-
squirrel monkey model….
...but the principal investigator 
was discredited and the research 
line was abrogated
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